石四藥集團(02005.HK):擁有在中國生產阿比多爾原料藥及製劑的領先公司 明早復牌
格隆匯2月5日丨石四藥集團(02005.HK)發佈公告,公司董事局注意到公司股份於今天的成交量及價格出現不尋常波動。
董事相信,股份成交量增加及股份價格波動乃由於近日傳媒新聞報導所致,據報導指,中國工程院院士、國家衞健委高級別專家成員李蘭娟在中國武漢公佈治療新型冠狀病毒(2019-nCoV)感染肺炎的最新研究成果。李蘭娟建議將阿比多爾和達蘆那韋列入國家衞健委《新型冠狀病毒感染的肺炎診療方案(試行第六版)》。集團擁有在中國生產阿比多爾原料藥及製劑的領先公司。
董事相信,於該公告刊發之時,傳媒新聞所報導有關李蘭娟的建議尚未經國家衞健委確認採納或列入國家衞健委《新型冠狀病毒感染的肺炎診療方案(試行第六版)》,而公司不能保證上述者即將落實,甚或不會落實。
誠如公司此前公告所載,為做好新型冠狀病毒(2019-nCoV)感染的疫情防控工作,中國各省市開通了首批相關防控藥品直接掛網採購綠色通道,或者將相關防控藥品直接納入應急採購範圍。集團抗病毒藥物阿比多爾膠囊已准入18個省份防控疫情產品儲備目錄或防控藥品綠色通道,另有11個省份即將按此方式完成准入工作。阿比多爾於2019年首次納入中國國家醫保目錄和納入中國國家衞健委發佈的抗病毒流感臨牀推薦使用藥物名單。於該公告刊發之時,阿比多爾膠囊已准入22個省份防控疫情產品儲備目錄或防控藥品綠色通道。
應公司要求,股份由2020年2月5日下午二時三十四分起於聯交所短暫停牌,以待刊發該公告。公司已向聯交所申請由2020年2月6日上午九時正起恢復公司股份買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.